Patients with lupus can present with diverse signs and symptoms affecting multiple organ systems. Lupus is a disease of progressive, and often irreversible, organ damage, which can lead to increased healthcare resource utilization and all-cause healthcare costs. Factors such as long-term use of corticosteroids and high disease activity may increase the risk of organ damage. Lupus nephritis, a serious manifestation of lupus, may lead to significant chronic kidney disease. Delays in treatment are another factor that may result in long-term organ damage. Modifying the natural course of the disease and minimizing corticosteroid exposure has been shown to prevent organ damage.

By the end of the program, you will be able to:

• Review the pathophysiology and clinical manifestations of lupus
• Discuss the clinical and economic impact of organ damage in the disease course of lupus
• Understand key components of disease modification and review strategies to prevent organ damage in lupus

Many patients with Major Depressive Disorder (MDD) require augmentation of their antidepressant with an additional therapy, and augmentation with an atypical antipsychotic is a guideline-recommended option for appropriate MDD patients. This session will focus on the burden of MDD and the impact of an atypical antipsychotic approved for the adjunctive treatment of MDD.

• Recognize the humanistic and economic burden of MDD.
• Describe where atypical antipsychotics fit within the treatment paradigm.
• Review the efficacy and safety data of an atypical antipsychotic as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults.

Please join a panel of four Managed Care Pharmacy Residency Program Directors (RPDs) from across the managed care industry who will provide an overview of residency accreditation and training, provide advice on navigating the application and interview processes, and answer questions residency candidates have about residency training. They will provide insights about the residency interview process, strong candidate characteristics, and what programs look for in applicants. Join us for an engaging dialogue.

Goal directed therapy is foundational to rational pharmacotherapy as well as the development of treatment guidelines. Importantly, treatment goals are not static and must evolve as a function of an evolving understanding of a given disease and the availability of more effective treatments. Innovations in rheumatology are enabling more patients to achieve higher levels of response and continue to facilitate the research necessary to define and refine treatment goals over time. 

The objective of this webinar is to review the evolution of goal directed therapy in rheumatology and discuss the clinical and health-economic value of goal-directed therapy and how payers can support goal-directed therapy.

Learning Objectives

• Review current treatment goals in rheumatology, progress toward goal attainment, and current practice patterns in rheumatology.
• Describe the clinical and health-economic value of achieving treatment goals in rheumatology and how payers can support goal directed therapy to improve the value of costly TIMs therapies.

Join us for an informative and engaging webinar where we will explore the changing landscape of digital communication between biopharma companies and healthcare decision makers (HCDMs). In this live session, we will delve into 3 key topics that are crucial for effective management in the digital era:

• The latest research on how HCDMs are utilizing digital resources and gain valuable insights into their preferences.
• How manufacturers are adapting to meet the evolving needs of HCDMs in a post-pandemic peak era.
• The transformative power of artificial intelligence in digital communications and the implications for dynamics between biopharma companies and HCDMs.

Did you know that pharmacists in managed health care organizations are responsible for the delivery of health care and prescription drug benefits to over 300 million Americans? Are you a student pharmacist, new to managed care pharmacy, or considering a career transition and want to better understand managed care pharmacy and its many career opportunities? Join members of the AMCP Membership Committee as we answer the question, "what is managed care pharmacy and what roles do pharmacists play in it?"

This PIE webinar will review zolbetuximab, an investigational therapy for use in combination with fluoropyrimidine and platinum chemotherapy for the 1L treatment of adult patients with metastatic or locally advanced unresectable human epidermal growth factor receptor 2-negative gastric/gastroesophageal junction adenocarcinoma whose tumors are Claudin 18.2 positive.

The safety and effectiveness of zolbetuximab have not been established; it is not approved by the FDA.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

This non-promotional, sponsored webinar will review health plan best practice recommendations for continuous glucose monitoring with an impressive panel of clinical and managed care experts.

As the US Market continues to evolve, so does the complexity of payers and providers navigating best practices that ensure their members have access to high-quality, cost-effective care. AMCP’s Market Insights Best Practice provides recommendations from our managed care members to help their peers make the best coverage and access decisions.

Continuous glucose monitoring (CGM) is a key intervention for advancing diabetes management and enhancing patient engagement and the care experience. Managed care and payer professionals remain instrumental in facilitating CGM access and related patient education efforts. Although diabetes technology has seen increased uptake over the past several years, recent innovation in CGM highlights an opportunity for optimal outcomes and quality improvement in managed care.

In this webinar, a panel of experts discuss health plan best practices related to continuous glucose monitoring. Following the presentation, join the panelists for a live Q&A session.

Learn About:

At the completion of this activity, participants should be able to:

• Optimizing outcomes with appropriate access and coverage of continuous glucose monitoring (CGM)
• Health plan best practice recommendations
• National health plan survey results
• Insights from a panel of diabetes and managed care experts

Explore the burden of disease, available treatments, and unmet needs in narcolepsy.